skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Ocugen's Founder-CEO Shankar Musunuri In Conversation With Scrip

The formation of any company involves blood, sweat and tears and the story has been no different for Ocugen Inc.

In an audio interview with Scrip, founder-CEO Shankar Musunuri gives us a glimpse of the journey and shares his excitement about two gene therapy candidates for eye diseases.

OCU-400, a candidate to treat retinitis pigmentosa and a rare genetic eye disorder, leber congenital amaurosis, will soon be heading to the clinic for human trials. OCU-410 for age-related macular degeneration is still in the preclinical stage but has a larger canvas, with the disease being a leading cause of visual impairment and blindness throughout the world.

The company has tied up with Chinese firm CanSino Biologics Inc. for developing these two candidates and Musunuri shares further commercialization plans.

Meanwhile, he emphasizes the good intentions behind trying to bring Bharat Biotech’s COVID-19 vaccine Covaxin to the US and Canada. The broad immunity it has demonstrated against variants like Delta and could potentially show against Omicron might give it an edge over Pfizer Inc. and Moderna, Inc.’s mRNA vaccines, Musunuri feels.

However, what does a clinical trial hold by the US Food and Drug Administration and a delay in filing for emergency use authorization in Canada mean for the vaccine and company? Find out in this podcast.

Time Stamps

0:11 Introduction

2:17 Advice for aspiring start-ups

3:55 Memorable and forgettable parts of entrepreneurship journey

7:38 Stressors and boosters

9:19 Way forward for COVID-19 vaccine post clinical hold

15:20 Will Pfizer beat Ocugen to the 2-5 age group?

16:38 Does the Omicron variant complicate matters?

22:37 Possibility of a booster

28:02 US class action suit

28:53 Mutation-agnostic gene therapy platform

36:18 CanSino Biologics’ agreement for OCU-400 and OCU-410

39:17 Risks in gene therapy development

 

Interview with Ocugen Founder-CEO Shankar Musunuri

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Related Stories

https://scrip.pharmaintelligence.informa.com/SC145448/Moderna-Co-Founder-Robert-Langers-Tips-For-Innovation

https://scrip.pharmaintelligence.informa.com/SC145501/Coronavirus-Update-Lukewarm-US-Panel-For-Molnupiravir-Inovio-Bharat-Look-At-Omicron

https://pink.pharmaintelligence.informa.com/PS145226/COVID-19-Vaccines-Ocugens-EUA-Request-For-Covaxin-In-Kids-Faces-Steep-Climb-At-US-FDA

https://scrip.pharmaintelligence.informa.com/SC144848/Can-Delta-Variant-Effectiveness-Fill-Brazil-Sized-Hole-In-Bharat-Biotechs-Prospects

https://scrip.pharmaintelligence.informa.com/SC145139/ExHilleman-CEO-On-COVID19-Vaccine-Heterologous-Boosting-Endemic-Disease

https://scrip.pharmaintelligence.informa.com/SC145104/Novartis-Doubles-Up-In-Optogenetics-With-Arctos-Buy

https://scrip.pharmaintelligence.informa.com/SC145457/Finance-Watch-Venture-Capital-Drives-Record-Breaking-Year-For-Cell-And-Gene-Therapies

 

 

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: